EUVIMEDEUVIMED entdecken
Crossref

Moving Tumor-Agnostic Therapy to the Big Stage: Translational and Molecular Oncology Highlights from the ESMO Congress 2025

Elisabeth Tregel, Damian T Rieke, Annalen Bleckmann, Christoph Benedikt Westphalen, Ina Pretzell, Sebastian Lange, Michael Quante, Linus D Kloker

Oncology Research and Treatment · 2026

DOI: 10.1159/000551042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology Research and Treatment, 2026. Verfasst von Elisabeth Tregel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Campus Benjamin Franklin, Universitätsmedizin Berlin, Freie Universität Berlin and Humb…. Hauptthemen laut MEDLINE: Neoplasms, Medical Oncology, Translational Research, Biomedical, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ESMO Congress 2025 in Berlin marked a milestone in precision oncology with the introduction of the first dedicated tumor-agnostic track, reflecting the shift from organ-based to molecularly defined cancer therapy. Across multiple sessions, updated data on biomarker-driven and pathway-based treatments demonstrated how targeted therapies can transcend histologic boundaries. Highlights included long-term results for approved tumor-agnostic agents (e.g., NTRK and BRAF-directed therapies, HER2-targeted antibody-drug conjugates [ADCs], as well as next-generation KRAS inhibitors, HER2- and TROP2-directed tyrosine kinase inhibitors and ADCs, and novel targets such as MTAP deletions, MET amplification, CD44v9 and MUC1. In parallel, advances in synthetic-lethality strategies beyond PARP inhibition and the clinical implementation of ctDNA-based minimal-residual-disease monitoring showcased how molecular profiling and liquid biopsies are reshaping treatment selection and response assessment. Taken together, these developments highlight the growing momentum in biomarker-guided and molecularly driven cancer care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsMedical OncologyTranslational Research, BiomedicalMolecular Targeted TherapyPrecision MedicineHumansBiomarkers, TumorAntineoplastic Agents

Stichwörter der Autor:innen

Association of Internal OncologyEuropean Society of Medical OncologyMolecular oncologyPrecision oncologyTargeted therapyTranslational oncologyTumor-agnostic agents

Substanzen

Biomarkers, TumorAntineoplastic Agents

Autor:innen und Institutionen

  • Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Campus Benjamin Franklin, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, elisabeth.tregel@charite.…
  • Charité Comprehensive Cancer Center, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, elisabeth.tregel@charite.de.
  • National Center for Tumor Diseases (NCT), NCT Berlin, a partnership between DKFZ, Charité Universitätsmedizin, Berlin Institute of Health at Charité (BIH) and Max Delbrück Center, Berlin, Germany, elisabeth.tregel@chari…
  • Med. Klinik m.S. Hämatologie, Onkologie und Tumorimmunologie, Campus Benjamin Franklin, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Charité Comprehensive Cancer Center, Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • National Center for Tumor Diseases (NCT), NCT Berlin, a partnership between DKFZ, Charité Universitätsmedizin, Berlin Institute of Health at Charité (BIH) and Max Delbrück Center, Berlin, Germany.

Zitieren

APA

Tregel, E., Rieke, D. T., Bleckmann, A., Westphalen, C. B., Pretzell, I., Lange, S., Quante, M., & Kloker, L. D. (2026). Moving Tumor-Agnostic Therapy to the Big Stage: Translational and Molecular Oncology Highlights from the ESMO Congress 2025. Oncology Research and Treatment. https://doi.org/10.1159/000551042

Vancouver

Tregel E, Rieke DT, Bleckmann A, Westphalen CB, Pretzell I, Lange S, et al. Moving Tumor-Agnostic Therapy to the Big Stage: Translational and Molecular Oncology Highlights from the ESMO Congress 2025. Oncology Research and Treatment. 2026. doi:10.1159/000551042

BibTeX
@article{Tregel2026,
  author = {Tregel, Elisabeth and Rieke, Damian T and Bleckmann, Annalen and Westphalen, Christoph Benedikt and Pretzell, Ina and Lange, Sebastian and Quante, Michael and Kloker, Linus D},
  title = {Moving Tumor-Agnostic Therapy to the Big Stage: Translational and Molecular Oncology Highlights from the ESMO Congress 2025},
  journal = {Oncology Research and Treatment},
  year = {2026},
  doi = {10.1159/000551042}
}
Kostenlos starten →